# Gene Therapy Market > Gene Therapy Market Research Report: Size, Share, Trend Analysis By Vector Type (Viral Vector (Lentiviral Vectors (LVVs), Retrovirus Vectors, Adenoviral Vectors (AdVs), Adeno-associated Viral Vectors (AAVs) and Non-Viral Vector (Physical Vector, Chemical Vector), by Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), By Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, and Others), by Delivery Method (In Vivo Gene Therapy and Ex Vivo Gene Therapy) and Region (North America, Europe, Asia-Pacific, Rest of the World)) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 19.04% - **2024:** $ 6.12 Billion - **2025:** $ 7.28 Billion - **2035:** $ 41.63 Billion - **Key Players:** Novartis (CH), Gilead Sciences (US), Spark Therapeutics (US), Bluebird Bio (US), Bristol-Myers Squibb (US), Sangamo Therapeutics (US), CRISPR Therapeutics (CH), AstraZeneca (GB), Roche (CH) **Report ID:** MRFR/Pharma/6927-CR · **Pages:** 167 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 02, 2026 **URL:** https://www.marketresearchfuture.com/reports/gene-therapy-market-8399 --- ## Market Summary ## **Gene Therapy Market Overview** The Gene Therapy Market was valued at USD 6.11 Billion in 2024. The Gene Therapy Market industry is projected to grow from USD 7.24 Billion in 2025 to USD 46.91 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 19.04% during the forecast period (2025-2035). The growing incidences and prevalence of cancer and rare disorders and increasing approval for gene therapy products and favourable government support for gene therapy are driving the growth of the Gene Therapy Market. As per the Analyst at MRFR, the growing incidences of cancer and rare disorders are significantly fueling the Gene Therapy Market as the demand for innovative treatments escalates. As cancer rates rise and the prevalence of rare genetic disorders increases, traditional therapeutic options often fall short, creating a pressing need for advanced solutions. Gene therapy, with its potential to address the underlying genetic causes of these conditions, offers a promising alternative by targeting and modifying the specific genes involved.  For instance, according to the International Agency for Research on Cancer, there were cancer cases of nearly 9,826,539 in Asia, 4,471,422 in Europe, 2,673 174 in Northern America, 1,551,060 in Latin America and the Caribbean, 1,185,216 in Africa, and 269 088 in Oceania cancer cases of both genders in 2022. Furthermore, India also reported increasing incidences of cancer, which is contributing to the growth of the global gene therapy market. ** Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review** ## **Gene Therapy Market****Opportunity** **GROWING INVESTMENT IN THE FIELD OF GENE THERAPY** The increasing investment in gene therapy is one of the major opportunities across the globe. The growing investment leads to an increase in the availability of technological advancements, including CRISPR-Cas9. Also, the investment assists in developing gene therapy with a focus on broad therapeutic areas. Furthermore, rising funding also assists in expanding the market, which fosters collaboration, competition, innovation, and investment. For instance, - June 2024: Beacon Therapeutics (US) has secured $170 million in Series B funding to propel its work on ophthalmic gene therapies. This round was led by Forbion, with participation from existing investors Syncona and Oxford Science Enterprises, along with new contributors TCGX and Advent Life Sciences. The funds are earmarked to advance the clinical development of their lead asset, AGTC-501, which is targeting X-Linked Retinitis Pigmentosa (XLRP), and to generate data for their Dry Age-related Macular Degeneration (dAMD) program. - February 2024: Vivet Therapeutics received USD 5.35 million in funding from the French government through the France Health Innovation Plan 2030, which will significantly boost the development of a gene therapy aimed at treating this rare and debilitating condition. CTX is a rare genetic disorder that impairs the body’s ability to metabolize cholesterol, leading to the accumulation of fatty deposits in various tissues, including the brain. This results in a range of serious symptoms, from chronic diarrhea in infancy to progressive neurological issues like dementia and seizures in adulthood. Currently, treatment options are limited to managing symptoms and slowing the progression of the disease. - January 2024: Novartis AG (Switzerland) signed a deal with Voyager Therapeutics (US) in order to pay USD 100 million upfront as a part of a licensing deal to develop gene therapy candidates for genetic disorders. - June 2023: Laurus Labs (India) invested USD 9.59 million for gene therapy firm ImmunoACT (India). ImmunoACT will be able to accelerate the scale-up of its lead candidate, HCAR-19, by expanding its multi-location cGMP facilities with the new funding. The data show a global increase in investment and collaboration in the gene therapy sector. Companies such as Beacon Therapeutics, Vivet Therapeutics, Novartis AG, and Laurus Labs are strategically collaborating and investing in R&D and manufacturing facilities to accelerate the commercialization and scaling-up of innovative gene therapies. ## **Gene Therapy Market****Segment Insights** ### **Gene Therapy****System by Vector Type Insights** Based on Vector Type, this segment includes Viral Vector (Lentiviral Vectors (LVVs), Retrovirus Vectors, Adenoviral Vectors (AdVs) and Adeno-associated Viral Vectors (AAVs)) and Non-Viral Vector (Physical Vector, Chemical Vector). The Viral Vector segment dominated the global market in 2024, while the Non-Viral Vector is projected to be the fastest–growing segment during the forecast period. Among viral vectors, adeno-associated viruses (AAVs) and lentiviral vectors (LVVs) are widely used for their safety profiles and long-term gene expression.  Non-viral vectors, including physical methods (like electroporation) and chemical carriers (like lipid nanoparticles), offer lower immunogenicity and easier large-scale manufacturing. The success of lipid nanoparticle-based mRNA vaccines during the COVID-19 pandemic has accelerated interest and innovation in non-viral delivery systems. Additionally, advancements in nanotechnology and material sciences are enhancing the efficiency and targeting capability of non-viral vectors, making them an attractive option for next-generation gene therapies and expanding their potential across various therapeutic areas. **FIGURE 2: GENE THERAPY MARKET SHARE BY VECTOR TYPE 2024 AND 2035 (USD BILLION)** Source: Secondary Research, Primary Research, MRFR Database and Analyst Review ### **Gene Therapy****System****by Gene Type****Insights** Based on Gene Type, this segment includes Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others. The Antigen segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. These therapies have shown remarkable clinical success and have received regulatory approvals, boosting market confidence. Additionally, antigen-based approaches are expanding into other areas such as infectious diseases and autoimmune disorders, supported by advancements in gene delivery technologies and personalized medicine.  The segment benefits from a robust pipeline, significant investment, and favorable regulatory designations like orphan drug and breakthrough therapy status, which accelerate development and commercialization. Overall, the antigen segment's ability to deliver targeted, effective, and personalized treatments positions it as a key driver of innovation and growth in the gene therapy landscape. ### **Gene Therapy****System****by Application****Insights** Based on Application, this segment includes Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, and Others. The Oncological Disorders segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. This is primarily due to the rising global cancer burden and the increasing adoption of gene therapies like [CAR-T cell therapy](../../../reports/car-t-cell-therapy-market-8102) and oncolytic viruses, which offer targeted and effective treatment options.  Advances in personalized medicine and immune-based gene therapies have shown significant success in treating hematologic and solid tumors, driving demand. Additionally, strong clinical pipelines, regulatory approvals, and substantial investments in cancer gene therapy research are fueling growth. The high unmet need for more effective cancer treatments and the ability of gene therapy to address previously untreatable cancers further strengthen this segment’s market position. ### **Gene Therapy****System****by Delivery Method****Insights** Based on the Delivery Method, this segment includes In Vivo Gene Therapy and Ex Vivo Gene Therapy. The In Vivo Gene Therapy segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. This method involves directly delivering genetic material into a patient’s body, allowing for simpler, less invasive procedures compared to Ex Vivo approaches. In Vivo therapies are particularly effective for treating genetic and rare diseases, especially those affecting the liver, muscles, and central nervous system.  The rise of adeno-associated viral ([AAV](../../../de/reports/adeno-associated-virus-aav-vector-based-gene-therapy-market-29672)) vectors and lipid nanoparticles has improved the safety and precision of in vivo delivery. Additionally, reduced complexity, lower treatment costs, and faster clinical translation are driving increased adoption. Growing research investments and successful clinical trials continue to accelerate development in this segment. ### **Gene Therapy****System Regional Insights** Based on the Region, the global Gene Therapy is segmented into North America, Europe, Asia-Pacific and Rest of the World. Major demand factors driving the North America market are the growing incidences and prevalence of cancer and rare disorders and increasing approval for gene therapy products and favourable government support for gene therapy. Additionally, the availability of reimbursements and insurance coverage is making gene therapies more accessible to patients. Increased healthcare expenditure and investment in research and development are further fueling market expansion.  Supportive regulatory frameworks and incentives are streamlining the approval process, while strategic partnerships and collaborations are accelerating innovation. The pipeline of gene therapy drugs includes a wide range of treatments for various genetic and acquired diseases, such as rare genetic disorders, cancer, and autoimmune diseases. The potential of these drugs to provide targeted and personalized treatments for patients with complex medical conditions has generated significant interest from biopharmaceutical companies, investors, and healthcare providers. The competitive landscape features established players who have adopted strategies such as acquisition, agreement, strategic alliance, collaboration, clinical trial, expansion, joint venture, new product development, and product approval to expand their product portfolio. **FIGURE 3: GENE THERAPY MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)** Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, Australia, Middle East & Africa, South America and others. **Global Gene Therapy Key Market Players & Competitive Insights** Many global, regional, and local vendors characterize the Gene Therapy Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market. The major competitors in the market are Bristol-Myers Squibb Company, Lonza, UniQure N.V., Bluebird Bio, Inc., Orchard Therapeutics Plc, GenSight Biologics, Novartis AG, Amgen Inc., Sarepta Therapeutics Inc., Spark Therapeutics, Inc., are among others. The Gene Therapy Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness. **Key Companies in the****Gene Therapy Market****include** - Bristol-Myers Squibb Company - [Lonza](https://www.lonza.com/specialized-modalities/cell-and-gene) - UniQure N.V. - Bluebird Bio, Inc. - Orchard Therapeutics Plc - GenSight Biologics - Novartis AG - Amgen Inc. - Sarepta Therapeutics Inc. - Spark Therapeutics, Inc., **Gene Therapy Market****Industry Developments** **January 2024:** Novartis AG has entered into a strategic partnership with Voyager Therapeutics, Inc., which includes an exclusive license for Voyager's TRACER capsids and related intellectual property. This collaboration will focus on developing a preclinical gene therapy candidate for Huntington's Disease (HD). **October 2023:** SpliceBio, a genetic medicines company specializing in Protein Splicing to advance gene therapies, has announced an exclusive collaboration and licensing agreement with Spark Therapeutics. This partnership will leverage SpliceBio's proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. **December 2023:**Bluebird bio, Inc. (US) received an approval from US Food Drug and Administration for Lyfgenia representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. **September 2021:** GenSight Biologics announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has designated its gene therapy LUMEVOQ as a Promising Innovative Medicine (PIM) for the treatment of vision loss caused by Leber Hereditary Optic Neuropathy (LHON), which is caused by a confirmed G11778A mutation in the ND4 mitochondrial gene. ## **Gene Therapy Market****Segmentation** ### **Gene Therapy by Vector Type Outlook** - Viral Vector - Lentiviral Vectors (LVVs) - Retrovirus Vectors - Adenoviral Vectors (AdVs) - Adeno-associated Viral Vectors (AAVs) - Non-Viral Vector - Physical Vector - Chemical Vector ### **Gene Therapy by Gene Type Outlook** - Antigen - Cytokine - Tumor Suppressor - Suicide - Deficiency - Growth Factors - Receptors - Others ### **Gene Therapy by Application Outlook** - Oncological Disorders - Rare Diseases - Cardiovascular Diseases - Neurological Disorders - Infectious Diseas - Others ### **Gene Therapy by Delivery Method Outlook** - In Vivo Gene Therapy - Ex Vivo Gene Therapy ### **Gene Therapy****Regional Outlook** - North America - US - Canada - Europe - Germany - France - UK - Italy - Spain - Rest of Europe - Asia-Pacific - China - India - Japan - South Korea - Australia - Rest of Asia-Pacific - Rest of the world - Middle East & Africa - South America ## Market Drivers ### Increasing Funding and Investment The Gene Therapy Market is experiencing a surge in funding and investment from both public and private sectors. Governments and venture capitalists are recognizing the potential of gene therapies to revolutionize treatment paradigms, leading to increased financial support for research initiatives. In recent years, funding for gene therapy projects has escalated, with billions of dollars allocated to support clinical trials and product development.   This influx of capital is likely to enhance the pace of innovation within the Gene Therapy Market, facilitating the development of new therapies that address unmet medical needs. Moreover, partnerships between biotech firms and academic institutions are becoming more common, further driving collaborative efforts to advance gene therapy research and commercialization. ### Growing Demand for Targeted Therapies The shift towards personalized and targeted therapies is a notable driver for the Gene Therapy Market. Patients and healthcare providers are increasingly seeking treatments that are tailored to individual genetic profiles, which gene therapies can provide. This trend is supported by advancements in genomics and biotechnology, enabling the development of therapies that address specific genetic mutations.   As of 2025, the market for targeted therapies is projected to grow substantially, reflecting a broader movement towards precision medicine. The Gene Therapy Market is well-positioned to capitalize on this demand, as it offers innovative solutions that align with the principles of personalized healthcare. Consequently, the emphasis on targeted therapies is likely to drive further investment and research in the gene therapy sector. ### Rising Prevalence of Genetic Disorders The increasing incidence of genetic disorders is a primary driver for the Gene Therapy Market. Conditions such as hemophilia, muscular dystrophy, and cystic fibrosis are becoming more prevalent, necessitating innovative treatment options. According to recent estimates, approximately 1 in 1,500 individuals are affected by hemophilia, highlighting the urgent need for effective therapies.   This growing patient population is likely to propel demand for gene therapies, as traditional treatments often fall short in efficacy. The Gene Therapy Market is thus positioned to expand significantly, as healthcare providers seek advanced solutions to address these complex genetic conditions. Furthermore, the rising awareness among patients and healthcare professionals about the potential of gene therapy to provide long-term solutions is expected to further stimulate market growth. ### Technological Advancements in Gene Editing Technological innovations in gene editing techniques, such as CRISPR-Cas9 and TALENs, are transforming the Gene Therapy Market. These advancements enable precise modifications to genetic material, enhancing the efficacy and safety of gene therapies. The ability to target specific genes with high accuracy has opened new avenues for treating previously untreatable conditions.   As of 2025, the market for gene editing technologies is projected to reach several billion dollars, indicating robust growth potential. This surge in technological capabilities is likely to attract significant investment, fostering further research and development in the Gene Therapy Market. Consequently, the integration of these cutting-edge technologies is expected to accelerate the approval and commercialization of novel gene therapies, thereby expanding the market landscape. ### Regulatory Support and Streamlined Approval Processes Regulatory bodies are increasingly providing support for the Gene Therapy Market by streamlining approval processes for new therapies. Initiatives aimed at expediting the review of gene therapies are being implemented, which could significantly reduce the time it takes for innovative treatments to reach the market.   For instance, the introduction of fast-track designations and priority review pathways is encouraging companies to invest in gene therapy development. This regulatory environment is likely to foster a more favorable landscape for the Gene Therapy Market, as it enhances the likelihood of successful product launches. As a result, the combination of supportive regulations and a growing pipeline of gene therapies is expected to contribute to the overall expansion of the market. ## Future Outlook The gene therapy market size is projected to grow at a 19.04% CAGR from 2024 to 2035, driven by advancements in gene therapy technology, increasing investments, and rising prevalence of genetic disorders. **New opportunities:** - Development of personalized gene therapies targeting rare diseases. - - Expansion of partnerships with biotech firms for innovative delivery systems. - Investment in AI-driven platforms for gene therapy research and development. By 2035, the Gene Therapy Market is expected to be a pivotal sector in healthcare innovation. ## Segment Insights ### By Vector Type: Viral Vector (Largest) vs. Non-Viral Vector (Fastest-Growing) In the Gene Therapy Market, the segment for vector type is predominantly led by viral vectors, which have established a strong foothold due to their efficiency and ability to deliver genetic material effectively. Non-viral vectors, while currently less dominant, are gaining traction as they offer advantages such as safety and scalability, driving a gradual shift in cell and gene therapy market dynamics. As more advancements are made in both types, the competition between them is intensifying, making the landscape increasingly complex. Vector Type: Viral Vector (Dominant) vs. Non-Viral Vector (Emerging) Viral vectors, including retroviruses, adenoviruses, and adeno-associated viruses, are recognized as the dominant technology in the Gene Therapy Market. They have been foundational in numerous clinical applications and trials, owing to their high efficiency in gene delivery and expression. Conversely, non-viral vectors, such as plasmid DNA and nanoparticles, are emerging due to their potential for safer applications and easier manufacturing processes. As researchers and companies innovate to enhance the delivery efficiency of non-viral systems, their adoption is anticipated to grow, marking a significant shift in the market dynamics between these two vector types. ### By Gene Type: Antigen (Largest) vs. Cytokine (Fastest-Growing) In the Gene Therapy Market, the gene types can be categorized into several segments, namely Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others. Among these, Antigen stands out as the largest segment, contributing significantly to the overall market share. Cytokines have emerged rapidly, demonstrating the fastest growth. Other gene types also show potential, but it is Antigen and Cytokine that dominate cell and gene therapy market discussions due to their substantial therapeutic implications and clinical advancements. Growth trends in the Gene Therapy Market for gene types reflect a dynamic landscape driven by advancements in biotechnology and increasing investment in research and development. The rising incidence of genetic disorders is propelling the demand for effective therapies, particularly those utilizing Antigens and Cytokines. Innovations in gene-editing technologies and increased collaboration among pharmaceutical companies are key drivers enabling these segments to thrive in the competitive market. Gene Type: Antigen (Dominant) vs. Cytokine (Emerging) Antigens occupy a dominant position in the Gene Therapy Market share due to their critical role in eliciting immune responses and treating various diseases. They are vital in vaccine development and cancer immunotherapy, establishing their importance in therapeutic applications. On the other hand, Cytokines represent an emerging segment, increasingly recognized for their potential in modulating immune responses and supporting tissue regeneration. Their rapid development is largely driven by advances in understanding cellular interactions and their therapeutic roles. As research evolves, the cell and gene therapy market is likely to see novel cytokine-based therapies entering the clinical landscape, thereby enhancing their position within the Gene Therapy Market. ### By Application: Oncological Disorders (Largest) vs. Rare Diseases (Fastest-Growing) Within the application segment of the Gene Therapy Market, Oncological Disorders hold the largest market share due to their complex treatment needs and research investments. This condition influences over half of the gene therapy developments as biopharmaceutical companies focus their efforts on delivering innovative therapies targeting various types of cancers. Rare Diseases, on the other hand, while smaller in market share, are seeing unprecedented growth. Their specialization and the emergence of orphan drugs are attracting significant attention, leading to rapid advancements and targeted therapies. Oncological Disorders (Dominant) vs. Rare Diseases (Emerging) The Oncological Disorders segment is characterized by a robust pipeline of gene therapies aimed at tackling an array of malignancies. This dominance is driven by the increasing incidence of cancer and growing public awareness about genetic factors influencing malignancies. Companies are investing heavily in gene-editing technologies and personalized medicine approaches to create innovative therapies. In contrast, the Rare Diseases segment is emerging rapidly, adapting to advancements in genetic research and patient-centric initiatives. Rare diseases often present unique challenges, requiring tailored therapies. The ascent of this segment reflects a rising commitment to treat conditions once deemed untreatable, with regulatory incentives facilitating faster development and approval processes. ### By Delivery Method: In Vivo Gene Therapy (Largest) vs. Ex Vivo Gene Therapy (Fastest-Growing) In the Gene Therapy Market, In Vivo Gene Therapy holds the largest share, representing a significant portion of the overall market. This segment benefits from its straightforward application process, wherein the therapeutic agents are directly delivered into the patient's body. It is widely utilized for various genetic disorders and diseases, making it a preferred choice among healthcare providers and patients. Meanwhile, Ex Vivo Gene Therapy, where cells are modified outside the body before being reintroduced, is rapidly gaining traction and is considered the fastest-growing segment. This method allows for a more controlled approach to gene delivery, catering to a niche but expanding market as tailored therapies become more prevalent. Delivery Method: In Vivo Gene Therapy (Dominant) vs. Ex Vivo Gene Therapy (Emerging) In Vivo Gene Therapy is the dominant method in this segment, known for its direct application in treating genetic conditions. By delivering genetic material directly into the patient's cells, it offers simplicity and effectiveness, appealing to a broad spectrum of applications. Conversely, Ex Vivo Gene Therapy is emerging as a significant alternative, characterized by its sophisticated modification processes that promise enhanced efficacy and safety. This method is particularly favorable for cancers and rare genetic disorders, facilitating personalized treatment approaches. Its rapid growth can be attributed to advancements in technology and increasing investments in research, leading to a higher adoption rate among healthcare institutions and research facilities. ## Regional Market Share Analysis ### North America : Leading Innovation and Investment North America accounted for the largest share of the global Gene Therapy Market size, reaching USD 2.8 billion in 2024. The region benefits from robust investment in research and development, a strong regulatory framework, and high demand for innovative therapies. The FDA's expedited approval processes for gene therapies have catalyzed market growth, making it a hub for biotech innovation. The United States is the primary driver of the gene market, with key players like Gilead Sciences, Spark Therapeutics, and Bluebird Bio leading the charge. The competitive landscape is characterized by significant collaborations between biotech firms and academic institutions, fostering innovation. Canada also plays a vital role, with increasing investments in gene therapy research and development, further solidifying North America's position as a leader in this field. ### Europe : Regulatory Advancements and Growth Europe is the second-largest market for gene therapy, holding approximately 30% of the global market share. The region is witnessing significant growth driven by advancements in regulatory frameworks, such as the European Medicines Agency's (EMA) guidelines for gene therapies. These regulations are designed to streamline the approval process, encouraging innovation and investment in the sector. Leading countries in Europe include Germany, France, and the United Kingdom, which are home to several key players like Novartis and AstraZeneca. The competitive landscape is evolving, with increasing collaborations between pharmaceutical companies and research institutions. The presence of a well-established healthcare infrastructure further supports the growth of gene therapy, making Europe a vital player in the global gene market. ### Asia-Pacific : Rapid Growth and Investment Asia-Pacific is rapidly emerging as a significant player in the gene therapy market, accounting for approximately 20% of the global market share. The region is driven by increasing investments in biotechnology, a growing patient population, and rising healthcare expenditures. Countries like China and Japan are at the forefront, with supportive government policies aimed at fostering innovation in gene therapies. China is particularly noteworthy, with a surge in clinical trials and a growing number of biotech firms entering the gene market. Japan's advanced healthcare system and regulatory support also contribute to the region's growth. The competitive landscape is characterized by both local and international players, including CRISPR Therapeutics and Sangamo Therapeutics, which are actively pursuing partnerships to enhance their market presence. ### Middle East and Africa : Emerging Market with Challenges The Middle East and Africa (MEA) region is still in the nascent stages of the gene therapy market, holding approximately 5% of the global market share. Growth is hindered by challenges such as limited healthcare infrastructure, regulatory hurdles, and a lack of funding for research and development. However, there is a growing interest in gene therapies, driven by increasing awareness and investment from both public and private sectors. Countries like South Africa and the UAE are beginning to invest in biotechnology, with initiatives aimed at improving healthcare access and innovation. The competitive landscape is still developing, with a few local players and international firms exploring opportunities in the region. As the healthcare infrastructure improves, the MEA region is poised for gradual growth in the gene therapy market. ## Competitive Benchmarking The Gene Therapy Market is currently characterized by a dynamic competitive landscape, driven by rapid advancements in technology and an increasing focus on personalized medicine. Key players such as Novartis (CH), Gilead Sciences (US), and Bluebird Bio (US) are at the forefront, leveraging their innovative capabilities to enhance treatment options for genetic disorders. Novartis (CH) has positioned itself as a leader through strategic partnerships and a robust pipeline of gene therapies, while Gilead Sciences (US) emphasizes its commitment to research and development, particularly in the area of rare diseases. Bluebird Bio (US), on the other hand, focuses on expanding its therapeutic offerings through collaborations, thereby shaping a competitive environment that is increasingly reliant on innovation and strategic alliances.   In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The Gene Therapy Market appears to be moderately fragmented, with a mix of established players and emerging biotech firms. This structure allows for a diverse range of therapeutic options, although the collective influence of major companies like Roche (CH) and Bristol-Myers Squibb (US) is significant, as they continue to invest heavily in research and development to maintain their competitive edge.   In August 2025, Gilead Sciences (US) announced a groundbreaking collaboration with a leading academic institution to develop next-generation gene editing technologies. This partnership is expected to accelerate the development of innovative therapies, potentially transforming treatment paradigms for genetic disorders. The strategic importance of this collaboration lies in Gilead's ability to leverage academic expertise, which may enhance its research capabilities and expedite the path to the gene market for new therapies.   In September 2025, Bluebird Bio (US) launched a new gene therapy product aimed at treating a rare genetic condition, following successful clinical trials. This launch not only diversifies Bluebird's portfolio but also underscores its commitment to addressing unmet medical needs. The strategic significance of this move is profound, as it positions Bluebird as a key player in the gene market, potentially increasing its market share and reinforcing its reputation for innovation.   In October 2025, Novartis (CH) expanded its gene therapy manufacturing capabilities by investing in a new facility in Switzerland. This strategic investment is likely to enhance production efficiency and scalability, allowing Novartis to meet growing global demand for its therapies. The implications of this expansion are substantial, as it may solidify Novartis's position as a leader in the gene therapy space, enabling it to respond swiftly to market needs and regulatory changes.   As of October 2025, the Gene Therapy Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains, thereby enhancing patient outcomes and driving market growth. ## Recent News & Developments **January 2024:** Novartis AG has entered into a strategic partnership with Voyager Therapeutics, Inc., which includes an exclusive license for Voyager's TRACER capsids and related intellectual property. This collaboration will focus on developing a preclinical gene therapy candidate for Huntington's Disease (HD). **October 2023:** SpliceBio, a genetic medicines company specializing in Protein Splicing to advance gene therapies, has announced an exclusive collaboration and licensing agreement with Spark Therapeutics. This partnership will leverage SpliceBio's proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. **December 2023:**Bluebird bio, Inc. (US) received an approval from US Food Drug and Administration for Lyfgenia representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. **September 2021:** GenSight Biologics announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has designated its gene therapy LUMEVOQ as a Promising Innovative Medicine (PIM) for the treatment of vision loss caused by Leber Hereditary Optic Neuropathy (LHON), which is caused by a confirmed G11778A mutation in the ND4 mitochondrial gene. ## Report Scope | MARKET SIZE 2024 | 6.12(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 7.285(USD Billion) | | MARKET SIZE 2035 | 41.63(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 19.04% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Novartis (CH), Gilead Sciences (US), Spark Therapeutics (US), Bluebird Bio (US), Bristol-Myers Squibb (US), Sangamo Therapeutics (US), CRISPR Therapeutics (CH), AstraZeneca (GB), Roche (CH) | | Segments Covered | Vector Type, Gene Type, Applications, Delivery Method | | Key Market Opportunities | Advancements in personalized medicine are driving growth in the Gene Therapy Market. | | Key Market Dynamics | Rising regulatory approvals and technological advancements are driving innovation and competition in the gene therapy market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Gene Therapy Market as of 2024?** A: The Gene Therapy Market was valued at 6.12 USD Billion in 2024. **Q: What is the projected market size for the Gene Therapy Market by 2035?** A: The market is projected to reach 41.63 USD Billion by 2035. **Q: What is the expected CAGR for the Gene Therapy Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Gene Therapy Market during 2025 - 2035 is 19.04%. **Q: Which companies are considered key players in the Gene Therapy Market?** A: Key players include Novartis, Gilead Sciences, Spark Therapeutics, and Bluebird Bio, among others. **Q: What are the main segments of the Gene Therapy Market based on vector type?** A: The main segments based on vector type are Viral Vector, valued at 25.0 USD Billion, and Non-Viral Vector, valued at 16.63 USD Billion. **Q: How do the different gene types perform in the Gene Therapy Market?** A: In 2024, Antigen and Tumor Suppressor gene types were valued at 5.5 USD Billion and 6.2 USD Billion, respectively. **Q: What applications dominate the Gene Therapy Market?** A: Oncological Disorders and Rare Diseases are leading applications, valued at 5.92 USD Billion and 8.12 USD Billion in 2024. **Q: What delivery methods are utilized in the Gene Therapy Market?** A: The market segments include In Vivo Gene Therapy, projected to reach 25.09 USD Billion, and Ex Vivo Gene Therapy, expected to reach 16.54 USD Billion. **Q: What is the potential growth of the Gene Therapy Market in the coming years?** A: The Gene Therapy Market appears poised for substantial growth, with projections indicating a significant increase by 2035. **Q: How does the Gene Therapy Market compare to other biopharmaceutical sectors?** A: The Gene Therapy Market, with its projected growth, suggests a robust position compared to other biopharmaceutical sectors, particularly in innovative treatments. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gene-therapy-market-8399*